Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 63 for:    Lixisenatide

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease (LixiPark)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03439943
Recruitment Status : Active, not recruiting
First Posted : February 20, 2018
Last Update Posted : August 25, 2020
Sponsor:
Collaborators:
Cure Parkinson
Réseau NS-Park
EUCLID
Sanofi
Information provided by (Responsible Party):
University Hospital, Toulouse

Tracking Information
First Submitted Date  ICMJE February 13, 2018
First Posted Date  ICMJE February 20, 2018
Last Update Posted Date August 25, 2020
Actual Study Start Date  ICMJE June 13, 2018
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 16, 2018)
Change from baseline to end-point (M12) in the MDS-UPDRS III motor ( Movement Disorder Society-Unified Parkinson's disease rating scale) [ Time Frame: 12 month ]
The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "disease-modifying" effect. The primary endpoint of this study is the change from baseline to end-point (M12) in the MDS-UPDRS III motor examination score, evaluated in the best ON condition in patients with early Parkinson's Disease.
Original Primary Outcome Measures  ICMJE
 (submitted: February 13, 2018)
Change from baseline to end-point (M12) in the MDS-UPDRS III motor [ Time Frame: 12 month ]
The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "disease-modifying" effect. The primary endpoint of this study is the change from baseline to end-point (M12) in the MDS-UPDRS III motor examination score, evaluated in the best ON condition in patients with early PD.
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Official Title  ICMJE Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease
Brief Summary The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "disease-modifying" effect.
Detailed Description

This study will be a French, multicenter parallel groups, 2-arm, randomized, placebo-controlled, double-blind, proof-of-concept (POC) phase II trial evaluating the effect of lixisenatide, in patients with early PD.

The treatment period will be followed by a wash-out period of 2 months.

JUSTIFICATION/CONTEXT Parkinson's disease (PD) is a common neurodegenerative disease. Currently available symptomatic treatments allow improving motor and to a lesser extent non-motor function in PD patients.

None of these treatments can slow down the underlining disease process and the relentless progression of motor and non-motor disability.

Several mechanisms including the aggregation of misfolded alphasynuclein, mitochondrial dysfunction, oxidative stress and neuroinflammation have been related to the pathogenesis of PD. Recent evidence further suggests the implication of cerebral insulin resistance in the neurodegenerative process, while glucagon-like peptide 1 receptor (GLP1-R) agonists that are approved for the treatment of type 2 diabetes have neuroprotective properties in animal models of PD (Aviles-Olmos et al., 2013a). Moreover, the results of a recent clinical pilot trial suggest that treatment with the GLP-1R agonist exenatide for 12 months improves motor function in patients with moderate PD . GLP1-R are widely expressed in the central nervous system and GLP1-R agonists such as liraglutide, lixisenatide and exenatide have measurable brain concentrations, which makes them suitable for treating brain disorders.

Lixisenatide is a well-tolerated GLP-1R agonist that can be administered once-daily (subcutaneous injection). It has demonstrated positive effects on learning and memory through an increase of hippocampal neurogenesis in preclinical models of obesity/diabetes. Furthermore, lixisenatide increases neurogenesis and decreases microglial activation in rodent models of Alzheimer's disease (APPswe/PS1ΔE9 mice and Aβ25-35 rats) (. At the same dose, lixisenatide showed higher effectiveness at activating brain GLP-1R than liraglutide and exenatide, and showed more effective neuroprotection in a variety of in-vitro models of neurodegeneration (WO2013/030409A1).

Thus, this randomized, double-blind, clinical trial now aim to evaluate the effects of lixisenatide, versus placebo, on both motor and non-motor PD symptoms in patients at an early stage of PD.

This study will involve centers of the French national Parkinson's disease and movement disorders research network (Ns-Park network).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Parkinson Disease
Intervention  ICMJE
  • Drug: Lixisenatide
    Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
    Other Name: injection drug
  • Drug: placebo
    Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
    Other Name: placebo injection
Study Arms  ICMJE
  • Experimental: Lixisenatide
    Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
    Intervention: Drug: Lixisenatide
  • Placebo Comparator: Placebo
    Placebo: once daily subcutaneous injection
    Intervention: Drug: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: August 24, 2020)
156
Original Estimated Enrollment  ICMJE
 (submitted: February 13, 2018)
158
Estimated Study Completion Date  ICMJE December 2021
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with PD according to UKPDSBB criteria (male or female).
  • Patient with a Hoehn and Yahr Stage <3 in the ON condition.
  • Patients aged from 40 to 75 years old.
  • Early-stage PD patients: diagnosis of PD for less than 3 years, without dyskinesia and motor fluctuations.
  • Patients treated with an "optimized" stable dopaminergic medication regimen (dopamine agonist and/or L-dopa and/or MAOB inhibitor) for at least 1 month before baseline.
  • Patients expected to remain on stable doses of antiparkinsonian medications for at least the first 6 months of the study and preferably for the 12 months of follow-up.
  • Patients (or caregiver) able to self-administer lixisenatide injection.
  • Patients with health insurance.
  • Patients who signed the written informed consent form.

Exclusion Criteria:

  • Patients suffering from other parkinsonian syndromes other than PD.
  • Patients expected not to be able to remain on stable doses of symptomatic antiparkinsonian medications for at least 6-month.
  • Patients with a Body Mass Index < 18.5
  • Patients suffering from type 1 or type 2 diabetes.
  • Malnutrition as assessed clinically by the investigator or any sub-investigator and by Mini Nutritional Assessment Short Form (MNA-SF) score <12 (the judgement of the investigator prevails over questionnaire scores).
  • Weight change of more than 5 kg in body weight during the last 3 months prior to screening.
  • Known history of drug or alcohol abuse within 6 months prior to the time of screening.
  • Patients with hyperthyroidism or uncontrolled hypothyroidism. Note: Patients diagnosed with hypothyroidism need to be on a stable thyroid replacement therapy for at least 6 weeks.
  • Patients with severe depression according to DSM criteria.
  • Patients with cognitive impairment (MoCA score <26).
  • Severe gastrointestinal disease (e.g. gastroparesis).
  • Patients previously exposed to a GLP-1 agonist.
  • Patients with severely impaired renal function (estimated creatinine clearance <30ml/min).
  • Patients with a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or ongoing symptomatic gallbladder disease.
  • Patients with any clinically significant ECG abnormality.
  • Laboratory findings at the time of screening:

Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range ALT or AST: >3 times ULN Total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome) Calcitonin: >20 pg/mL (5.9 pmol/L) Hemoglobin: <11 g/dL (male/female) and/or neutrophils <1,500/mm3 and/or platelets <100,000/mm3 Triglyceride (TG): >600 mg/dL (6.78 mmol/L). History of unexplained pancreatitis, chronic pancreatitis or pancreatectomy.

  • Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes).
  • Hyperlipidemia.
  • Females who are pregnant, breast feeding or of child bearing age without effective contraception.
  • Patients treated per os in the evening by drugs requiring a rapid action (at the discretion of the investigator).
  • Participants who lack the capacity to give informed consent.
  • Any medical or psychiatric condition which may compromise participation in the study or the safety, at the discretion of the investigator.
  • Known abnormality on CT or MRI brain imaging that is considered likely to compromise compliance with any aspect of the trial.
  • Prior intra-cerebral surgical intervention for PD.
  • Participant under legal guardianship or incapacitation.
  • Patients who are participating or have participated in another interventional clinical trial within 30 days prior to baseline.
  • Previous enrolment in the present trial.
  • Allergic reaction to the active substance or to any of the excipients of lixisenatide
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03439943
Other Study ID Numbers  ICMJE RC31/16/8912
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University Hospital, Toulouse
Study Sponsor  ICMJE University Hospital, Toulouse
Collaborators  ICMJE
  • Cure Parkinson
  • Réseau NS-Park
  • EUCLID
  • Sanofi
Investigators  ICMJE
Principal Investigator: Olivier. RASCOL, MD, PHD University Hospital, Toulouse
PRS Account University Hospital, Toulouse
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP